Breast Cancer Action, a nonprofit education and advocacy organization, says it can’t get its message on billboards in Indianapolis, home of the Eli Lilly pharmaceutical company.
The message:
“Eli Lilly is making us sick. Tell them to stop”
Breast Cancer Action says they’ve been rejected by every billboard company in Indianapolis. The group states:
“Despite working within the guidelines of each billboard company contacted, the advocacy group has been turned down because of the content of the message. At a time when political advertizing across the nation has reached an all time high, the rejection of BCA’s message raises critical questions about who controls the media when it comes to public health.
“We are talking about women’s health here. A breast cancer organization’s message about the impact of a drug company’s behavior is being kept off billboards in the company’s home town. When corporate influence runs this deep, the public should be outraged. We certainly are,” said BCA executive director, Barbara Brenner.
The public’s health is at stake. Eli Lilly is the sole worldwide manufacturer of rBGH (recombinant bovine growth hormone also known as rBST) which is sold under the name Posilac and has long been linked to cancer. The artificial hormone is given to dairy cows to stimulate milk production.
Breast Cancer Action’s “Milking Cancer” campaign demands Eli Lilly stop manufacturing the artificial stimulant rBGH.”
Here’s a “Milking Cancer” video posted on the Breast Cancer Action site:
Milking Cancer from Breast Cancer Action on Vimeo.
Opinions on other issues in news, journals, PR, advertising, marketing
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like